

10th Urologic Oncology:

Advances in Clinical Practice

November 20-21, 2015

MD Anderson, Dan L. Duncan Building
Floor 8 Conference Center, 1155 Pressler, Houston, Texas

CALL FOR ABSTRACTS

Abstracts will be selected for poster presentation at the conference.

Please submit abstracts via e-mail to urologiconcology@mdanderson.org.

Deadline for submission is **September 30, 2015**. Authors of selected abstracts will be notified via e-mail early October 2015.

THE UNIVERSITY OF TEXAS

MDAnderson
Cancer Center

Making Cancer History®



Urologic Oncology:

Advances in Clinical Practice

Focus

The 10th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced bladder, prostate, kidney, penile and testis cancers.

Educational Objectives

After attending the conference, participants should be able to

- Properly counsel patients with rare cancers such as penile and testicular cancer on the best available treatment options, taking into account the potential benefit of robotic surgery for tumor management (*Knowledge, Competence, Performance, Patient Outcomes*);
- Appropriately integrate the numerous technology-driven advances into cancer management using surgery, radiation, and chemotherapeutics, as well as diagnostics and staging (*Knowledge, Competence, Performance, Patient Outcomes*);
- Select patients for procedures or systemic therapies correctly, and appropriately manage toxicities and complications from treatment (*Knowledge, Competence, Performance, Patient Outcomes*);
- Integrate surgery and topical or systemic therapy into the management of urothelial cancer patients, while identifying rare variants or complex case scenarios that might be better served by referral to a tertiary center to improve patient care (*Knowledge, Competence, Performance, Patient Outcomes*).

Educational Methods

Lectures – Case Presentations – Panel Discussions – Audience Response System – Question and Discussion Sessions

Target Audience

This conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants.

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/ Credit Designation

Physicians

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing

Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 16.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding *AMA PRA Category 1 Credit™* or certificates documenting attendance will be distributed to participants as they depart the symposium. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Call for Abstracts

Abstracts will be selected for poster presentation at the conference. Please submit abstracts via e-mail to urologiconcology@mdanderson.org. The deadline for submission is September 30, 2015. Authors of selected abstracts will be notified via e-mail in early October 2015.

MD Anderson Organizing Committee

Conference Chairs

Christopher G. Wood, MD

Program Chairman
Professor and Vice Chairman
Urology

Nizar M. Tannir, MD

Program Co-Chairman
Professor and Vice Chairman
Genitourinary Medical Oncology

Brian F. Chapin, MD

Program Co-Chairman
Assistant Professor
Urology

Conference Committee

Ana Aparicio, MD

Associate Professor
Genitourinary Medical Oncology

John W. Davis, MD

Associate Professor
Urology

Colin P. Dinney, MD

Professor and Chairman
Urology

Jose A. Karam, MD

Assistant Professor
Urology

Jay B. Shah, MD

Assistant Professor
Urology

Arlene O. Siefker-Radtke, MD

Associate Professor
Genitourinary Medical Oncology

Carol Fourtunia

Sr. Administrative Assistant
Urology

Constance C. Tierney, CMP

Manager
CME/Conference Management

Program

Friday, November 20, 2015

7:00 a.m. Registration and Continental Breakfast

8:00 **Welcome and Opening Remarks**

Christopher G. Wood, MD
Nizar M. Tannir, MD
Brian F. Chapin, MD

Session I: Renal Cancer

Moderator: Jose A. Karam, MD

Debate #1: What is the Best Management for a Small, Incidentally Found Renal Mass?

8:05 **Active Surveillance**

Surena F. Matin, MD

8:20 **Energy Ablation**

Kamran Ahrar, MD

8:35 **Surgery**

Jose A. Karam, MD

Debate #2: Should a Lymph Node Dissection Accompany the Resection of Locally Advanced Renal Cell Carcinoma?

8:50 **Yes**
Christopher G. Wood, MD

9:05 **No**
Jeffrey J. Tomaszewski, MD

Debate #3: What is the Best Management for Patients That Present With $\geq$ T1b Renal Tumors

9:20 **Radical Nephrectomy**
Christopher G. Wood, MD

9:35 **Nephron Sparing**
Jose A. Karam, MD

9:50 **Update on the Status of Adjuvant and the Neoadjuvant Therapy in the Management of Locally Advanced Renal Cell Carcinoma in 2015**
Christopher G. Wood, MD

10:05 **Questions**

10:10 Break

10:30 **Management of IVC Thrombus and Locally Recurrent RCC**
Jose A. Karam, MD

10:45 **Management of Indeterminate Pulmonary Nodules in Patients With Renal Tumors**
Mehrad Adibi, MD

11:00 **Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma: What You Need to Know in 2015**
Eric Jonasch, MD

11:15 **Immunotherapy for Renal Cell Carcinoma in 2015: Is it Finally Center Stage?**
Nizar M. Tannir, MD

11:35 **Systemic Therapy for Non-Clear Cell Histology: Are There Any Good Options?**
Nizar M. Tannir, MD

11:55 **Questions and Case Presentations**
Moderator: Christopher G. Wood, MD

Panelists: Mehrad Adibi, MD; Kamran Ahrar, MD; Eric Jonasch, MD; Jose A. Karam, MD; Surena F. Matin, MD; George N. Thalmann, MD; Jennifer Wang, MD

12:30 p.m. Lunch (Provided)

Session II: Prostate Cancer

Moderator: Brian F. Chapin, MD

Debate #1: Cancer-Specific Survival After Local Therapy for Prostate Cancer: Which is Better?

1:15 **Surgery**
Louis L. Pisters, MD

1:30 **Radiation**
Seungtaek Choi, MD

1:45 **Cutting Edge Lecture #1: Tips and Tricks: MRI Fusion Biopsy**
John F. Ward, MD

2:05 **Cutting Edge Lecture #2: Next Generation Prostate Cancer Diagnosis**
John W. Davis, MD

Debate #2: All Gleason 6 Cancers Should be on Active Surveillance

2:25 **Yes**
Jeri Kim, MD

2:40 **No**
Curtis A. Pettaway, MD

2:55 **Questions**

3:00 Break

3:20 **State of the Art Translational Science Lecture: The Androgen Receptor and its Impact on Therapy Success and Duration**
Ana Aparicio, MD

3:40 **Surgical Outcomes Forum: The Apical Dissection - Technique and Quality of Life Outcomes**
John W. Davis, MD

4:00 **Control of the Primary Tumor in the Setting of Metastatic Prostate Cancer: Does It Make Sense?**
Brian F. Chapin, MD

4:20 **Challenging Cases in Prostate Cancer**
Presenters: Curtis A. Pettaway, MD; Louis L. Pisters, MD; John F. Ward, MD
Panelists: Brian F. Chapin, MD; Seungtaek Choi, MD; John W. Davis, MD; Eleni Efstathiou, MD, PhD; Edward M. Messing, MD, PhD; Sumit K. Subudhi, MD, PhD; George N. Thalmann, MD

5:15 Break

5:30 **Andrew C. von Eschenbach Lectureship**
Edward M. Messing, MD

6:00 Welcome Reception

Saturday, November 21, 2015

7:00 a.m. Registration and Continental Breakfast

Session III: Urothelial Cancer

Moderator: H. Barton Grossman, MD

Debate #1: What is the Best Treatment for T1 High Grade Bladder Cancer?

8:00 **BCG**
Mehrad Adibi, MD

8:15 **Cystectomy**
Colin P. Dinney, MD

Debate #2: What is the Best Treatment for BCG Refractory CIS?

8:30 **More BCG**
Colin P. Dinney, MD

8:45 **Intravesical Chemotherapy**
Jay B. Shah, MD

9:00 **Cystectomy**
Neema Navai, MD

9:15 **State of the Art Lecture**
**Molecular Profiling Urothelial Malignancies:
Insights Into Tumor Biology and Therapeutic Targets**
David J. McConkey, PhD

Changing the Way We Do Things: Cystectomy

9:30 **Robotics**
Neema Navai, MD

9:50 **Enhanced Recovery**
Jay B. Shah, MD

Questions

10:00 Break

Debate #3: Who Should Get Neoadjuvant Chemotherapy?

10:25 **Give to All T2 Bladder Cancer Patients**
Colin P. Dinney, MD

10:35 **Give Only to High Risk T2 Bladder Cancer Patients**
H. Barton Grossman, MD

10:45 **Give to No T2 Bladder Cancer Patients,
There's Always Adjuvant Therapy**
Arlene O. Siefker-Radtke, MD

10:55 **Limitations in Bladder Cancer Clinical Staging**
Neema Navai, MD

11:10 **Advances in Chemotherapy and Targeted Therapy
for Urothelial Carcinoma**
Arlene O. Siefker-Radtke, MD

11:25 **Immunotherapy for Bladder Cancer: The New Frontier**
Jianjun Gao, MD, PhD

Case Presentations

Moderator: Jay B. Shah, MD

Panelists: Colin P. Dinney, MD; Ashish Kamat, MD;
Edward M. Messing, MD; Neema Navai, MD;
Arlene O. Siefker-Radtke, MD; George N. Thalmann, MD

12:30 p.m. Lunch (Provided)

Distinguished Alumni Lectures

1:15 **Urology**
George N. Thalmann, MD

1:35 **Genitourinary Medical Oncology**
Gabriel Malouf, MD, PhD

1:55 **State of the Art Lecture**
Circulating Biomarkers in Genitourinary Cancers
Amado Zurita-Saavedra, MD

2:10 **The Coming Revolution in Healthcare:**
Value-Based Medicine
Jay B. Shah, MD

Session IV: Rare Genitourinary Tumors

Moderator: Curtis A. Pettaway, MD

2:25 **Endoscopic Management of Upper Tract Urothelial**
Carcinoma: Tricks of the Trade
Surena F. Matin, MD

2:45 **Surgical Innovations in the Treatment of Localized and**
Locally Advanced Penile Carcinoma
Curtis A. Pettaway, MD

3:05 **Systemic Therapy Options for Adrenocortical Carcinoma**
Mouhammed A. Habra, MD

3:25 **Questions**

3:30 Break

3:50 **New Biological Insights in Non-Seminomatous**
Germ Cell Tumors?
Shi-Ming Tu, MD

Debate #1: What is the Best Treatment for High Risk Stage 1
Testis Cancer?

4:05 **Observation**
Scott E. Delacroix, Jr., MD

4:20 **Chemotherapy**
Matthew Campbell, MD

4:35 **RPLND**
John N. Papadopoulos, MD

4:50 Questions

4:55 Adjourn

MD Anderson Faculty

Mehrad Adibi, MD
Assistant Professor
Urology

Kamran Ahrar, MD
Professor
Interventional Radiology

Ana Aparicio, MD
Associate Professor
Genitourinary Medical
Oncology

Matthew Campbell, MD
Assistant Professor
Genitourinary Medical
Oncology

Brian F. Chapin, MD
Assistant Professor
Urology

Seungtaek Choi, MD
Associate Professor
Radiation Oncology

John W. Davis, MD
Associate Professor
Urology

Colin P. Dinney, MD
Professor & Chairman
Urology

Eleni Efstathiou, MD, PhD
Associate Professor
Genitourinary Medical
Oncology

Jianjun Gao, MD, PhD
Assistant Professor
Genitourinary Medical
Oncology

H. Barton Grossman, MD
Clinical Professor
Urology

Mouhammed A. Habra, MD
Associate Professor
Endocrine Neoplasia
and HD

Eric Jonasch, MD
Associate Professor
Genitourinary Medical
Oncology

Ashish Kamat, MD
Professor
Urology

Jose A. Karam, MD
Assistant Professor
Urology

Jeri Kim, MD
Associate Professor
Genitourinary Medical
Oncology

Surena F. Matin, MD
Professor
Urology

David J. McConkey, PhD
Professor
Urology - Research

Neema Navai, MD
Assistant Professor
Urology

John N. Papadopoulos, MD
Assistant Professor
Urology

Curtis A. Pettaway, MD
Professor
Urology

Louis L. Pisters, MD
Professor
Urology

Jay B. Shah, MD
Assistant Professor
Urology

Arlene O. Siefker-Radtke, MD
Associate Professor
Genitourinary Medical
Oncology

Sumit K. Subudhi, MD, PhD
Assistant Professor
Genitourinary Medical
Oncology

Nizar M. Tannir, MD, FACP
Professor & Vice Chairman
Genitourinary Medical
Oncology

Jeffrey J. Tomaszewski, MD
Assistant Professor, Surgery
Assistant Director,
Genitourinary Oncology
MD Anderson Cancer
Center at Cooper
Camden, New Jersey

Shi-Ming Tu, MD
Professor
Genitourinary Medical
Oncology

Jennifer Wang, MD
Assistant Professor
Genitourinary Medical
Oncology

John F. Ward, MD
Associate Professor
Urology

Christopher G. Wood, MD
Professor & Vice Chairman
Urology

Amado Zurita-Saavedra, MD
Assistant Professor
Genitourinary Medical
Oncology

Guest Faculty

Scott E. Delacroix, Jr., MD

Assistant Professor
Department of Urology
LSU Health
Metairie, Louisiana

Distinguished Alumni

Gabriel Malouf, MD, PhD

Assistant Professor
University Pierre and Marie Curie
Department of Medical Oncology
Paris, France

George N. Thalmann, MD

Director, Department of Urology
Anna-Seilr-Haus
Inselspital
Bern, Switzerland

Andrew C. von Eschenbach Lecture

Edward M. Messing, MD

Professor & Chairman
Department of Urology
University of Rochester Medical Center
School of Medicine and Dentistry
Rochester, New York

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Registration Information

On-site registration opens at 7:00 a.m. on Friday, November 20, 2015. The conference will begin at 8:00 am on Friday, November 20, 2015 and adjourn on Saturday, November 21, 2015 at 4:55 p.m. Advance registration is encouraged as space and materials are limited. Please see the registration form for applicable fees.

The full conference registration fee includes the tuition, program, continental breakfasts, breaks, lunches, and reception.

The deadline for advance registration is Friday, October 30, 2015.

There are three ways to register:

1. On-line at www.mdanderson.org/conferences
2. Mail to:
CME/Conference Management – Unit
1781, The University of Texas MD
Anderson Cancer Center, P.O. Box
301407, Houston, TX 77230-1407
3. Fax to: 713-794-1724

We accept the following forms of payment:

1. Check (payable through U.S. banks only)
2. Money Order
3. Credit Cards (MasterCard, VISA, and American Express)
4. Cash (on-site registration only)

When registering online a receipt/confirmation letter will be automatically e-mailed to the e-mail address you list on the registration form. If you register by fax or mail, a receipt/confirmation letter will be sent to you within ten working days of receipt of your fee.

Refund/Cancellation Policy: The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **October 30, 2015.**

No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations

- A block of rooms has been reserved for conference attendees at the Houston Marriott Medical Center, 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested. To make reservations, please call Reservations at 713-796-0080 and identify yourself as part of the

MD Anderson Urologic Oncology Conference

- The special meeting rate is \$125.00 single or double occupancy. Please add 17% Texas State and local taxes.
- Reservations and deposits received after October 29, 2015 will be confirmed if space is available and at current hotel published guest room rates.

Ground Transportation (prices are subject to change and variable depending on location of conference)

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).

- Taxicabs are available at an estimated cost for \$50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott Medical Center for \$27 one-way and \$54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at www.supershuttle.com.
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott Medical Center for \$24 one-way and \$48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at www.supershuttle.com.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

CONFERENCE REGISTRATION - 176700/114640

10th Urologic Oncology: Advances in Clinical Practice — November 20-21, 2015

Last Name	First	MI	Highest Degree
Department (include unit no.)		Specialty	
Institution			
MD Anderson Employee ID No. (required for all MDACC employees):		Physician ☐ Yes ☐ No	
Street			
City		State/Foreign Country/Zip or Mail Code	
Daytime Phone (with area code)		Cell Phone (with area code)	Fax (with area code)
E-mail Address (please print)			
Emergency Contact	Phone (with area code)	Charge the following: ☐ VISA ☐ MasterCard ☐ American Express	
Credit Card Holder Name (First/Last)		Credit Card Holder Billing Address & ZIP Code	
Credit Card Number		Expiration Date	
MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted			
Business Unit	Department	Fund Group *	Fund Type
Authorized Signature REQUIRED for credit card or IDT			
IDT Approver Name (First/Last) please print			

THIS IS NOT A SELF-MAILER - Address to:
9th Urologic Oncology: Advances in Clinical Practice
November 20-21, 2015

Department of CME/Conference Management
Unit 1781

The University of Texas MD Anderson Cancer Center
PO Box 301407, Houston, TX 77230-1407
or fax to 713-794-1724

Make check or money order payable to:

The University of Texas MD Anderson Cancer Center

GENERAL CONFERENCE REGISTRATION FEES

Physicians

- ☐ Postmarked before October 30, 2015 \$250.00
- ☐ Postmarked after October 30, 2015 \$300.00

Students / Trainees / PAs /

Advanced Nurse Practitioners

- ☐ Postmarked before October 30, 2015 \$60.00
- ☐ Postmarked after October 30, 2015 \$80.00

Department of CME/Conference Management - Unit 1781
The University of Texas MD Anderson Cancer Center
#176700/30/114640/41; PS104258
PO Box 301407
Houston, TX 77230-1407

Non-Profit Org.
U.S. Postage
PAID
Permit No. 7052
Houston, TX